Analysts' ratings for Compass (NYSE:COMP) over the last quarter vary from bullish to bearish, as provided by 12 analysts. Summarizing their recent assessments, the table below illustrates the evolving ...
COMPASS Pathways is a small developmental concern in the psychedelic drug market, currently developing a psilocybin therapy for treatment-resistant depression. The company recently presented positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results